Plain-English translation of NCT04095299 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
Rectal cancer is traditionally treated with surgery, but recent studies suggest that some patients may be able to avoid surgery if their tumors shrink completely with radiation and chemotherapy. This trial is testing whether giving a higher dose of radiation therapy — combined with capecitabine chemotherapy — works better than a standard radiation dose at helping early-stage rectal cancer patients preserve their rectum and skip surgery altogether.
Doctors want to know if increasing the radiation dose can improve outcomes for patients with smaller, early-stage rectal cancers who want to avoid surgery. Right now, there isn't clear evidence about what the best radiation dose should be for these patients, so this trial aims to answer that question.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to receive either standard-dose or high-dose radiation therapy, both given five days a week for about six weeks. During the same period, you will also take capecitabine chemotherapy pills twice daily on weekdays. The radiation targets your tumor and surrounding tissue to try to shrink it completely, ideally allowing you to keep your rectum and avoid surgery. Your doctors will monitor your progress closely throughout treatment and afterward to see how well your tumor responds.
AI-generated summary from trial data · Aug 14, 2026 · Not medical advice
Denmark